Key Highlights
- Anthony Mancini, Chief Global Commercialization Officer, offloaded 26,552 shares valued at approximately $3.5M on March 25 through a pre-arranged 10b5-1 trading plan
- Shares opened at $94.29, reflecting a 1.3% decline, within a 52-week trading band of $29.17–$124.49
- Truist Financial elevated RVMD to “strong-buy” status on March 26, aligning with optimistic calls from Jefferies, Evercore, UBS, and Wedbush
- Company insiders have collectively divested approximately 149,592 shares (roughly $15M) over the last three months, while institutions control 94.34% of outstanding shares
- Fourth quarter 2025 earnings per share registered at -$1.86, falling short of the -$1.56 analyst consensus due to elevated R&D and administrative expenditures
Shares of Revolution Medicines (RVMD) began trading Wednesday, March 26 at $94.29, marking a 1.3% decrease from the previous session.
Revolution Medicines, Inc., RVMD
On March 25, Anthony Mancini, who serves as the company’s Chief Global Commercialization Officer, executed a sale of 26,552 shares totaling around $3.5 million. The share prices in these transactions ranged between $93.22 and $97.21.
These stock sales occurred pursuant to a Rule 10b5-1 trading arrangement that Mancini established on December 24, 2025. Such predetermined plans allow executives to schedule transactions in advance, suggesting these sales don’t necessarily reflect immediate concerns about the company’s prospects.
Concurrently, Mancini exercised stock options to purchase 37,450 shares priced at $33.62 each, amounting to approximately $1.26 million. Following these combined transactions, his direct holdings include 54,400 shares plus 54,400 restricted stock units.
Mancini’s activity represents just part of a broader pattern. Mark A. Goldsmith, another company insider, disposed of 12,871 shares on March 17 at an average price of $99.48, generating proceeds exceeding $1.28 million. That same day, CFO Jack Anders sold 2,753 shares at an identical price point, collecting roughly $274,000.
Across the previous 90-day period, company insiders have collectively sold approximately 149,592 shares valued at $15 million. Current insider ownership represents 8.20% of the company.
Truist Financial Issues Strong-Buy Recommendation
The insider transactions haven’t deterred Wall Street analysts from maintaining bullish stances. On March 26, Truist Financial elevated RVMD to a “strong-buy” rating.
Evercore issued an identical recommendation earlier on February 25. Jefferies launched coverage with a “buy” rating on March 16. UBS likewise initiated coverage with a “buy” designation on February 27.
Weiss Ratings stands as the solitary bearish voice, maintaining a “sell (d-)” recommendation. According to MarketBeat’s aggregated consensus, the stock carries a “Buy” rating with a mean price objective of $78.94 — significantly beneath current trading levels.
Individual analyst projections show greater optimism. Piper Sandler established a $120 target (Overweight rating), Wells Fargo set expectations at $144, and Needham projects $145 with a Buy recommendation.
Institutional Capital Influx Continues Despite Quarterly Shortfall
Institutional investors have substantially increased their positions recently. Norges Bank established a fresh stake valued at approximately $195.6 million during Q4. Avoro Capital entered with holdings worth roughly $172.8 million. UBS expanded its position by 183.6%, accumulating 3,087,937 shares now valued near $246 million. Polar Capital dramatically increased its stake by 321.2%, currently maintaining over 2 million shares.
Institutional stakeholders collectively control 94.34% of RVMD.
This institutional enthusiasm persists despite the company’s Q4 2025 earnings disappointment. Revolution Medicines reported a per-share loss of $1.86, compared to Wall Street’s anticipated -$1.56, representing a $0.30 shortfall. Management attributed the variance to research and development investments and selling, general, and administrative costs exceeding projections.
Revenue performance wasn’t problematic — the company concluded the quarter maintaining $2.03 billion in cash and investment holdings, partially bolstered by a strategic arrangement with Royalty Pharma. Wall Street forecasts a full fiscal 2026 EPS of -$3.49.
RVMD currently trades with a 50-day moving average of $101.53 and a 200-day moving average of $78.24. The biotechnology firm commands a market capitalization of $18.69 billion.
Over the trailing twelve months, RVMD has delivered a remarkable 145% gain. During the most recent six-month period, shares have climbed 112%.
